Gejl M, Gjedde A, Egefjord L, et al
In a phase 2 clinical trial for obesity, 26 weeks of efinopegdutide (doses 5 to 10mg) resulted in up to 11.8% WL in people with obesity (without diabetes) compared to 7.5% WL with liraglutide 3 mg and 1.8% WL with placebo [77, 78]
In particolare: Regimi alimentari inadeguati, ad esempio frequente in chi segue una dieta vegana fai da te, senza il supporto di un nutrizionista
IV delivery changes the equation
In a 2025 review, the authors describe this species as occupying an extraordinary niche in the human gut, and a model organism studied for its ability to modulate human health and gut microbiome structure.13 In animal studies, it has slowed the development and progression of diabetes , obesity , and irritable bowel disease .14 In human trials, it has helped participants reduce their BMI and improve their diabetic markers.12 Its effects on obesity and diabetes have been recreated in humans as well
combined with many local anesthetics Neffy Figure 3
